We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01960205
Recruitment Status : Unknown
Verified September 2014 by Xinli Zhou,MD,PHD, Shandong Provincial Hospital.
Recruitment status was:  Recruiting
First Posted : October 10, 2013
Last Update Posted : September 25, 2014
Chinese Medical Association
Information provided by (Responsible Party):
Xinli Zhou,MD,PHD, Shandong Provincial Hospital

Brief Summary:
The purpose of the study is to examine the effect of Saxagliptin in the newly diagnosed people with pre-diabetes and obesity besides lifestyle intervention ,there to evaluate DPP 4 inhibitors of reversing pre-diabetes curative effect to normal blood sugar, and observe its influences on the targets of obesity related metabolic abnormalities, to explore new ways for intervention on populations with pre-diabetes and obesity .

Condition or disease Intervention/treatment Phase
Prediabetes Drug: Saxagliptin Drug: saxagliptin Drug: metformin Other: lifestyle intervention Phase 4

Detailed Description:

Materials and Methods: This is a perspectiveness ,randomized, opening study, patients will be randomly assigned to the standarddose Saxagliptin group ,the lifestyle intervention group,the Metformin group and the low dose Saxagliptin group with a 6-month treatment period.

Oral glucose tolerance test will examined before and 6 months post-treatment during the trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity
Study Start Date : August 2013
Estimated Primary Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prediabetes
Drug Information available for: Saxagliptin

Arm Intervention/treatment
Experimental: Standarddose Saxagliptin
Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
Drug: Saxagliptin
5mg a day for 6 months
Other Name: Onglyza

Active Comparator: Lifestyle intervention
Lifestyle intervention for 6 months
Other: lifestyle intervention
lifestyle intervention for 6 months
Other Name: living way intervention

Active Comparator: Metformin
Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
Drug: metformin
500mg three times a day for 6 months
Other Name: melbine

Experimental: low dose Saxagliptin
Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
Drug: saxagliptin
2.5 mg a day for 6 months
Other Name: Onglyza

Primary Outcome Measures :
  1. oral glucose tolerance test [ Time Frame: Change of Blood sugar from baseline at 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1.Newly diagnosed insulin resistance or glucose intolerance .

2.20 to 70 years of age.

3.BMI≥28kg/m2,or BMI>25kg/m2 beside waistline≥80cm(female),≥90cm(male).

Exclusion Criteria:

  1. Under Diabetes Mellitus treatment.
  2. Allergy to dipeptidyl peptidase 4 (DPP-4) inhibitors .
  3. Active heart failure.
  4. Unwilling or unable to sign inform consents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01960205

Layout table for location contacts
Contact: Xinli Zhou, MD,PhD 15168889976 zhouxinli0301@163.com

Layout table for location information
China, Shandong
Shandong Provincial Hospital Recruiting
Jinan, Shandong, China, 250021
Contact: Xinli Zhou, MD, PhD    15168889976    zhouxinli0301@163.com   
Principal Investigator: Xinli Zhou, MD,PhD         
Sponsors and Collaborators
Shandong Provincial Hospital
Chinese Medical Association
Layout table for investigator information
Principal Investigator: Xinli Zhou, MD, PhD Shandong Provincial Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Xinli Zhou,MD,PHD, Xinli Zhou, Shandong Provincial Hospital
ClinicalTrials.gov Identifier: NCT01960205    
Other Study ID Numbers: ZXL-201308
First Posted: October 10, 2013    Key Record Dates
Last Update Posted: September 25, 2014
Last Verified: September 2014
Keywords provided by Xinli Zhou,MD,PHD, Shandong Provincial Hospital:
Saxagliptin, prediabetes, glucose intolerance,obesity
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Prediabetic State
Glucose Intolerance
Nutrition Disorders
Body Weight
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action